6:10 PM
 | 
Jan 07, 2013
 |  BC Extra  |  Company News

Vertex's CF products receive first breakthrough designations

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said FDA granted Breakthrough Therapy Designation for its cystic fibrosis (CF) drug Kalydeco ivacaftor as monotherapy and for Kalydeco plus Vertex's VX-809. Vertex said the designations, which were created by the FDA Safety and Innovation Act, are the first to be issued by FDA. The...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >